Samrat Pharmachem Limited has formally declared to BSE Limited that it does not meet the criteria to be classified as a Large Corporate under SEBI regulations. The company submitted this declaration on April 7, 2026, as part of its regulatory compliance obligations.

Regulatory Declaration Details

The pharmaceutical chemicals manufacturer confirmed its status through an official communication to the Department of Corporate Services at BSE Limited. The declaration specifically references SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which establishes the criteria for Large Corporate classification.

Corporate Governance Compliance

The declaration was properly executed with dual authorization from key company officials. Company Secretary & Compliance Officer Nishant Kankaria and Chief Financial Officer Rajesh Mehta both digitally signed the document, ensuring adherence to corporate governance protocols.

Samrat Pharmachem Limited operates as a manufacturer and exporter of pharmaceutical chemicals, with its registered office and factory located in GIDC Phase 4, Ankleshwar, Gujarat, and corporate office in Andheri West, Mumbai.

Regulatory Significance

This declaration ensures the company remains compliant with SEBI's disclosure requirements regarding Large Corporate status. The SEBI circular establishes specific criteria that entities must meet to be classified as Large Corporates, with corresponding regulatory obligations and disclosure requirements.

Samrat Pharmachem Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited. The pharmaceutical chemicals manufacturer filed the mandatory Certificate under Regulation 74(5) for the quarter ended March 31, 2026, demonstrating adherence to regulatory requirements.

Regulatory Compliance Details

The certificate was issued by MUFG Intime India Private Limited, the company's registrar and transfer agent, and subsequently submitted to BSE Limited on April 7, 2026. Company Secretary and Compliance Officer Nishant Kankaria signed the submission letter, ensuring proper corporate governance protocols were followed.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during Q4FY26 were properly processed within prescribed timelines. The registrar verified that security certificates received for dematerialisation were confirmed or rejected appropriately, with physical certificates being mutilated and cancelled after due verification.

Corporate Information

Samrat Pharmachem Limited operates as a manufacturer and exporter of pharmaceutical chemicals. The company maintains its registered office and factory at Plot No. A2/3444-3445, GIDC, Phase 4, Ankleshwar, Gujarat, while its corporate office is located in Mumbai. The company's CIN is L24230GJ1992PLC017820.

Compliance Framework

The submission fulfills SEBI's requirement for listed companies to provide quarterly certificates confirming proper handling of dematerialisation processes. This regulatory framework ensures transparency in securities handling and maintains investor confidence in the dematerialisation system. The certificate confirms that the company's registrar has substituted depository names in the register of members as registered owners within prescribed timelines.